ATOMWISE BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Atomwise Business Model Canvas: AI Drug-Discovery Blueprint for Investors
Unlock Atomwise's strategic playbook with our concise Business Model Canvas-see how AI-driven drug discovery converts data and partnerships into dealflow and revenue, where margins and risks sit, and which growth levers matter most; download the full Word/Excel canvas for a ready-to-use, investor-grade blueprint to benchmark or build your own strategy.
Partnerships
$1.2 Billion Strategic Alliance with Sanofi
This foundational alliance with Sanofi, signed late 2022 and running through 2026, funds discovery on up to five targets; Atomwise took a $20 million upfront and can earn >$1.2 billion in R&D, development, and sales milestones plus tiered royalties, reflecting AtomNet's validated capacity for large-scale pharma R&D and contributing materially to 2025 revenue guidance.
AIMS Program with 1,000+ Academic Institutions
By March 2026 Atomwise's AIMS program reached 1,000+ academic labs, creating a decentralized R&D engine that delivered >120,000 experimental readouts and accelerated 430 target validations; Atomwise provides AI screening in return for data and first-look licensing rights.
Joint Venture with SEngine Precision Medicine
The joint venture with SEngine Precision Medicine pairs SEngine's 3D tumor organoid platform and real-patient cellular data with Atomwise's AI screening to target personalized oncology therapies; in 2025 the program targets reducing trial failure rates-currently ~90% in oncology-aiming to cut that by 20-30% and accelerate candidates into INDs, supporting Atomwise's precision-medicine push.
Infrastructure Alliance with AWS and NVIDIA
Atomwise partners with Amazon Web Services and NVIDIA to run GPU-accelerated cloud HPC, enabling screening of a 3+ trillion-compound library and executing billions of simulations daily; this infrastructure supports the speed advantage that drove Atomwise to a projected 2025 revenue run-rate of roughly $120M and kept compute costs below 18% of R&D spend in 2025.
- 3+ trillion synthesizable compounds
- billions of GPU simulations per day
- AWS + NVIDIA GPU clusters
- 2025 revenue run-rate ≈ $120M
- compute ≤18% of 2025 R&D spend
Co-development Pact with BridgeBio Pharma
Atomwise's co-development pact with BridgeBio Pharma targets rare genetic diseases by using AI to design small molecules for previously undruggable targets BridgeBio identified; Atomwise led discovery while BridgeBio funds and runs trials, sharing milestones and royalties.
As of FY2025 the collaboration aims to advance 4 programs, with Atomwise eligible for up to $220M in milestones plus low-double-digit royalties, letting Atomwise scale a diversified pipeline without bearing clinical costs.
- Focus: rare genetic diseases; AI small-molecule discovery
- Structure: Atomwise discovery; BridgeBio clinical execution
- Risk/reward: shared; Atomwise: discovery fees, $220M max milestones, low-double-digit royalties
- 2025 programs: 4 active programs; clinical costs borne by BridgeBio
- Benefit: diversified portfolio without clinical overhead
High‑value pharma alliances, AI compute scale, and faster oncology INDs
Key partners: Sanofi (2022-26 deal: $20M upfront, >$1.2B milestones/royalties), BridgeBio (4 FY2025 programs; up to $220M milestones, low‑double‑digit royalties), SEngine JV (precision oncology; target IND acceleration -20-30% failure reduction), AWS+NVIDIA (3+ trillion library; Billions GPUs/day; 2025 run‑rate ≈$120M; compute ≤18% R&D).
| Partner | 2025 KPIs | Financials |
|---|---|---|
| Sanofi | 5 targets; validated AtomNet | $20M upfront; >$1.2B milestones |
| BridgeBio | 4 programs | Up to $220M; low‑double‑digit royalties |
| SEngine | Oncology IND acceleration -20-30% | JV terms undisclosed |
| AWS + NVIDIA | 3+T compounds; billions sims/day | Supports ~$120M 2025 run‑rate; compute ≤18% R&D |
What is included in the product
Detailed Word Document
A focused Business Model Canvas for Atomwise detailing its AI-driven drug discovery value propositions, customer segments (biopharma partners, researchers), channels, revenue streams and cost structure aligned to real-world operations and investor needs.
Customizable Excel Spreadsheet
High-level view of Atomwise's business model highlighting AI-driven drug discovery, partnerships, and revenue streams in an editable one-page canvas to quickly pinpoint strategic and operational pain relievers.
Activities
Virtual Screening of 3 Trillion+ Compounds
Atomwise uses AtomNet to screen a proprietary library exceeding 3 trillion synthesizable molecules (2026), replacing wet-lab high‑throughput screens and trimming lead ID from years to weeks; internal benchmarks report >10x faster hit discovery and cost savings estimated at $50-150M per major program.
Internal Pipeline Development for 36+ Programs
Atomwise has pivoted to proprietary R&D with 36+ internal programs as of Q1 2026, focusing on immunology targets TYK2, RIPK1, and RIPK2; these programs aim for IND-enabling studies with projected 2026 R&D spend of ~$120-140M supporting advancement toward clinical trials.
AI Model Training and Structural Refinement
Continuous refinement of the AtomNet convolutional neural network is central, training on a database of over 10 million protein-ligand structures and ~250 million simulated binding poses to cut lead discovery time by ~40% versus 2020.
By 2026 Atomwise's AI predicts ADMET profiles, reducing late-stage attrition by ~30% and improving candidate success probability from 6% to ~9%, with iterative learning improving prediction accuracy ~18% year-over-year.
Target Identification and Lead Optimization
Atomwise partners with pharma to find novel binding sites on proteins once thought inaccessible, using AI to flag hits and then optimize molecular structures for potency and safety; this service drove Atomwise to sign 38 discovery collaborations in FY2025, generating $64.2M in discovery revenue.
- Identifies novel binding sites on disease proteins
- Optimizes hits for potency and safety
- Primary value-add for early-stage pipelines
- 38 collaborations, $64.2M discovery revenue in FY2025
Data Curation and Proprietary Knowledge Mapping
Atomwise spends over $40M annually on data curation-integrating 150+ academic collaborations, 60M public records, and proprietary assays-to supply its deep-learning models and avoid garbage-in, garbage-out. In 2026 this curated dataset is valued by management as a top non-software asset, underpinning a drug discovery pipeline with >$2.3B projected peak-market value.
- Annual data spend: $40M+
- Collaborations: 150+ partners
- Public records integrated: 60M entries
- Valuation impact: supports >$2.3B pipeline potential
Atomwise: AtomNet screens 3T+ molecules, $2.3B pipeline, $64M revenue, $120-140M R&D
Atomwise runs AtomNet to screen >3T synthesizable molecules, powers 36+ internal programs, spent ~$120-140M R&D in 2026, and earned $64.2M discovery revenue in FY2025; data curation >$40M/year supports models trained on 10M+ structures and 250M poses, underpinning >$2.3B pipeline value.
| Metric | Value |
|---|---|
| Library size | >3T |
| Internal programs | 36+ |
| R&D spend (2026) | $120-140M |
| FY2025 revenue | $64.2M |
| Data spend/year | $40M+ |
| Training data | 10M structures; 250M poses |
| Pipeline value | >$2.3B |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Atomwise Business Model Canvas, not a mockup or sample; it shows the real structure and content you'll receive after purchase.
When you complete your order, you'll get this identical file in editable formats, fully formatted for presentation and immediate use.
No placeholders or teaser content-what you see is the deliverable in full, ready to edit, share, and apply to strategic planning.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Atomwise Business Model Canvas: AI Drug-Discovery Blueprint for Investors
Unlock Atomwise's strategic playbook with our concise Business Model Canvas-see how AI-driven drug discovery converts data and partnerships into dealflow and revenue, where margins and risks sit, and which growth levers matter most; download the full Word/Excel canvas for a ready-to-use, investor-grade blueprint to benchmark or build your own strategy.
Partnerships
$1.2 Billion Strategic Alliance with Sanofi
This foundational alliance with Sanofi, signed late 2022 and running through 2026, funds discovery on up to five targets; Atomwise took a $20 million upfront and can earn >$1.2 billion in R&D, development, and sales milestones plus tiered royalties, reflecting AtomNet's validated capacity for large-scale pharma R&D and contributing materially to 2025 revenue guidance.
AIMS Program with 1,000+ Academic Institutions
By March 2026 Atomwise's AIMS program reached 1,000+ academic labs, creating a decentralized R&D engine that delivered >120,000 experimental readouts and accelerated 430 target validations; Atomwise provides AI screening in return for data and first-look licensing rights.
Joint Venture with SEngine Precision Medicine
The joint venture with SEngine Precision Medicine pairs SEngine's 3D tumor organoid platform and real-patient cellular data with Atomwise's AI screening to target personalized oncology therapies; in 2025 the program targets reducing trial failure rates-currently ~90% in oncology-aiming to cut that by 20-30% and accelerate candidates into INDs, supporting Atomwise's precision-medicine push.
Infrastructure Alliance with AWS and NVIDIA
Atomwise partners with Amazon Web Services and NVIDIA to run GPU-accelerated cloud HPC, enabling screening of a 3+ trillion-compound library and executing billions of simulations daily; this infrastructure supports the speed advantage that drove Atomwise to a projected 2025 revenue run-rate of roughly $120M and kept compute costs below 18% of R&D spend in 2025.
- 3+ trillion synthesizable compounds
- billions of GPU simulations per day
- AWS + NVIDIA GPU clusters
- 2025 revenue run-rate ≈ $120M
- compute ≤18% of 2025 R&D spend
Co-development Pact with BridgeBio Pharma
Atomwise's co-development pact with BridgeBio Pharma targets rare genetic diseases by using AI to design small molecules for previously undruggable targets BridgeBio identified; Atomwise led discovery while BridgeBio funds and runs trials, sharing milestones and royalties.
As of FY2025 the collaboration aims to advance 4 programs, with Atomwise eligible for up to $220M in milestones plus low-double-digit royalties, letting Atomwise scale a diversified pipeline without bearing clinical costs.
- Focus: rare genetic diseases; AI small-molecule discovery
- Structure: Atomwise discovery; BridgeBio clinical execution
- Risk/reward: shared; Atomwise: discovery fees, $220M max milestones, low-double-digit royalties
- 2025 programs: 4 active programs; clinical costs borne by BridgeBio
- Benefit: diversified portfolio without clinical overhead
High‑value pharma alliances, AI compute scale, and faster oncology INDs
Key partners: Sanofi (2022-26 deal: $20M upfront, >$1.2B milestones/royalties), BridgeBio (4 FY2025 programs; up to $220M milestones, low‑double‑digit royalties), SEngine JV (precision oncology; target IND acceleration -20-30% failure reduction), AWS+NVIDIA (3+ trillion library; Billions GPUs/day; 2025 run‑rate ≈$120M; compute ≤18% R&D).
| Partner | 2025 KPIs | Financials |
|---|---|---|
| Sanofi | 5 targets; validated AtomNet | $20M upfront; >$1.2B milestones |
| BridgeBio | 4 programs | Up to $220M; low‑double‑digit royalties |
| SEngine | Oncology IND acceleration -20-30% | JV terms undisclosed |
| AWS + NVIDIA | 3+T compounds; billions sims/day | Supports ~$120M 2025 run‑rate; compute ≤18% R&D |
What is included in the product
Detailed Word Document
A focused Business Model Canvas for Atomwise detailing its AI-driven drug discovery value propositions, customer segments (biopharma partners, researchers), channels, revenue streams and cost structure aligned to real-world operations and investor needs.
Customizable Excel Spreadsheet
High-level view of Atomwise's business model highlighting AI-driven drug discovery, partnerships, and revenue streams in an editable one-page canvas to quickly pinpoint strategic and operational pain relievers.
Activities
Virtual Screening of 3 Trillion+ Compounds
Atomwise uses AtomNet to screen a proprietary library exceeding 3 trillion synthesizable molecules (2026), replacing wet-lab high‑throughput screens and trimming lead ID from years to weeks; internal benchmarks report >10x faster hit discovery and cost savings estimated at $50-150M per major program.
Internal Pipeline Development for 36+ Programs
Atomwise has pivoted to proprietary R&D with 36+ internal programs as of Q1 2026, focusing on immunology targets TYK2, RIPK1, and RIPK2; these programs aim for IND-enabling studies with projected 2026 R&D spend of ~$120-140M supporting advancement toward clinical trials.
AI Model Training and Structural Refinement
Continuous refinement of the AtomNet convolutional neural network is central, training on a database of over 10 million protein-ligand structures and ~250 million simulated binding poses to cut lead discovery time by ~40% versus 2020.
By 2026 Atomwise's AI predicts ADMET profiles, reducing late-stage attrition by ~30% and improving candidate success probability from 6% to ~9%, with iterative learning improving prediction accuracy ~18% year-over-year.
Target Identification and Lead Optimization
Atomwise partners with pharma to find novel binding sites on proteins once thought inaccessible, using AI to flag hits and then optimize molecular structures for potency and safety; this service drove Atomwise to sign 38 discovery collaborations in FY2025, generating $64.2M in discovery revenue.
- Identifies novel binding sites on disease proteins
- Optimizes hits for potency and safety
- Primary value-add for early-stage pipelines
- 38 collaborations, $64.2M discovery revenue in FY2025
Data Curation and Proprietary Knowledge Mapping
Atomwise spends over $40M annually on data curation-integrating 150+ academic collaborations, 60M public records, and proprietary assays-to supply its deep-learning models and avoid garbage-in, garbage-out. In 2026 this curated dataset is valued by management as a top non-software asset, underpinning a drug discovery pipeline with >$2.3B projected peak-market value.
- Annual data spend: $40M+
- Collaborations: 150+ partners
- Public records integrated: 60M entries
- Valuation impact: supports >$2.3B pipeline potential
Atomwise: AtomNet screens 3T+ molecules, $2.3B pipeline, $64M revenue, $120-140M R&D
Atomwise runs AtomNet to screen >3T synthesizable molecules, powers 36+ internal programs, spent ~$120-140M R&D in 2026, and earned $64.2M discovery revenue in FY2025; data curation >$40M/year supports models trained on 10M+ structures and 250M poses, underpinning >$2.3B pipeline value.
| Metric | Value |
|---|---|
| Library size | >3T |
| Internal programs | 36+ |
| R&D spend (2026) | $120-140M |
| FY2025 revenue | $64.2M |
| Data spend/year | $40M+ |
| Training data | 10M structures; 250M poses |
| Pipeline value | >$2.3B |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Atomwise Business Model Canvas, not a mockup or sample; it shows the real structure and content you'll receive after purchase.
When you complete your order, you'll get this identical file in editable formats, fully formatted for presentation and immediate use.
No placeholders or teaser content-what you see is the deliverable in full, ready to edit, share, and apply to strategic planning.
